文献速递治疗药物监测与药物基因组学

英国初级保健患者对药物基因组学药物的纵向暴露分析

Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing.
PubMed 文献 · Br J Clin Pharmacol · 2019-12-13

2011-12年58%患者至少被处方1种此类药物,既往20年增至80%;CYP2D6、CYP2C19和SLCO1B1解释>95%处方,为预emptive检测设计提供依据。

要点

  • 初级保健中药物基因组学药物暴露极常见,随年龄增长而增加。
  • CYP2D6、CYP2C19和SLCO1B1覆盖>95%相关处方。
  • 多数患者暴露于多种药物,支持预emptive多基因检测设计。

核心结论

  • 初级保健患者对药物基因组学药物的暴露非常普遍、多重且始于相对较早的成年期。
  • 少数药物基因组解释大多数处方,可指导预emptive检测设计。

研究设计与样本

  • 总结1993-2017年处方,回顾性(2、10、20年)和前瞻性(5年)描述暴露。

主要发现

  • 2011-12年58%患者被处方至少1种药物基因组学药物,既往20年增至80%。
  • 未来5年内47%患者被处方≥2种、7%被处方≥5种药物基因组学药物。
  • 既往20年≥70岁患者89%被处方至少1种,50-59岁患者71%被处方至少1种。
  • 处方最多的药物用于镇痛、胃保护、精神疾病和心血管疾病。
  • CYP2D6、CYP2C19和SLCO1B1解释>95%的药物基因组学药物处方。

临床怎么用

  • 提示初级保健可考虑预emptive药物基因组检测,重点关注CYP2D6、CYP2C19和SLCO1B1。
  • 检测设计需覆盖多种常用药物,因多重暴露常见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate the longitudinal exposure of English primary care patients to pharmacogenomic drugs to inform design of pre-emptive testing. METHODS: Sixty-three drugs were identified with dosing guidelines based on variants of 19 pharmacogenes in the Pharmacogenomics Knowledgebase on 01 September 2018. Prescribing of these pharmacogenomic drugs between 1993 and 2017 was summarised for a sample of 648 141 English patients aged 50-99 years on 01 January 2013, registered with Clinical Practice Research Datalink practices during 2011-12. Exposure of patients to pharmacogenomic drugs retrospectively (2, 10, 20 y) and prospectively (5 y) was described. RESULTS: During 2011-12, 58% of patients were prescribed at least 1 pharmacogenomic drug, increasing to 80% over the previous 20 years. Multiple exposure was common, with 47% patients prescribed ≥2 pharmacogenomic drugs and 7% prescribed ≥5 pharmacogenomic drugs over the next 5 years. The likelihood of exposure to pharmacogenomic drugs increased with age, with 89% patients ≥70 years prescribed at least 1 pharmacogenomic drug over the previous 20 years. Even among those aged 50-59 years, 71% were prescribed at least 1 pharmacogenomic drug over the previous 20 years. The pharmacogenomic drugs prescribed to the most patients were for pain relief, gastroprotection, psychiatric and cardiovascular conditions. Three pharmacogenes (CYP2D6, CYP2C19 and SLCO1B1) accounted for >95% pharmacogenomic drugs prescribed. CONCLUSIONS: In primary care patients, exposure to pharmacogenomic drugs is extremely common, multiplicitous and has commenced by relatively early adulthood. A small number of pharmacogenes account for the majority of drugs prescribed. These findings could inform design of pre-emptive pharmacogenomic testing for implementation in primary care.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Kimpton JE, Carey IM, Threapleton CJD, et al. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing. Br J Clin Pharmacol. 2019. PMID: 31454087. doi:10.1111/bcp.14100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。